PT2003120E - Derivados de azapéptido como inibidores de protease de hiv - Google Patents

Derivados de azapéptido como inibidores de protease de hiv

Info

Publication number
PT2003120E
PT2003120E PT08252023T PT08252023T PT2003120E PT 2003120 E PT2003120 E PT 2003120E PT 08252023 T PT08252023 T PT 08252023T PT 08252023 T PT08252023 T PT 08252023T PT 2003120 E PT2003120 E PT 2003120E
Authority
PT
Portugal
Prior art keywords
protease inhibitors
hiv protease
azapeptide derivatives
azapeptide
derivatives
Prior art date
Application number
PT08252023T
Other languages
English (en)
Inventor
Scott L Harbeson
Roger D Tung
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of PT2003120E publication Critical patent/PT2003120E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
PT08252023T 2007-06-12 2008-06-12 Derivados de azapéptido como inibidores de protease de hiv PT2003120E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29

Publications (1)

Publication Number Publication Date
PT2003120E true PT2003120E (pt) 2010-02-11

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
PT08252023T PT2003120E (pt) 2007-06-12 2008-06-12 Derivados de azapéptido como inibidores de protease de hiv

Country Status (26)

Country Link
US (4) US20090036357A1 (pt)
EP (3) EP2322509B1 (pt)
JP (1) JP2010529196A (pt)
KR (2) KR101185899B1 (pt)
CN (2) CN101711237B (pt)
AR (1) AR066972A1 (pt)
AT (2) ATE447554T1 (pt)
AU (1) AU2008267048C1 (pt)
BR (2) BRPI0813911A2 (pt)
CA (1) CA2692028C (pt)
CO (1) CO6241121A2 (pt)
CY (1) CY1109766T1 (pt)
DE (1) DE602008000255D1 (pt)
DK (1) DK2003120T3 (pt)
ES (3) ES2394952T3 (pt)
HK (2) HK1136576A1 (pt)
HR (1) HRP20100065T1 (pt)
MX (1) MX2009013565A (pt)
PL (1) PL2003120T3 (pt)
PT (1) PT2003120E (pt)
RS (1) RS51226B (pt)
RU (2) RU2448958C2 (pt)
SI (1) SI2003120T1 (pt)
TW (1) TW200908970A (pt)
WO (1) WO2008156632A1 (pt)
ZA (1) ZA200909079B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241289A1 (en) * 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
WO2008156632A1 (en) 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
WO2010041241A2 (en) * 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hiv-1 integrase derived peptides and compositions
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
EP2515877B1 (en) * 2009-12-21 2016-08-10 Janssen Sciences Ireland UC Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
SI2720989T1 (sl) 2011-06-20 2016-11-30 H. Lundbeck A/S Devterirani 1-piperazino-3-fenil indani za zdravljenje shizofrenije
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
WO2017095761A1 (en) * 2015-12-02 2017-06-08 Merck Sharp & Dohme Corp. Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
EP3813800A1 (en) * 2018-06-29 2021-05-05 Incyte Corporation Formulations of an axl/mer inhibitor
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
CA3180487A1 (en) * 2020-04-16 2021-10-21 The Medical College Of Wisconsin, Inc. Aerosolized formulations of hiv protease inhibitors for the treatment of airway reflux

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216172A (en) 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ATE230402T1 (de) 1992-12-29 2003-01-15 Abbott Lab Hemmer der retroviralen protease
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
HU229938B1 (en) 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
YU12204A (sh) * 2001-08-31 2006-08-17 Bristol Myers Squibb Company Korišćenje atazanavira u terapiji hiv-a
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2676567A1 (en) 2003-02-21 2005-03-31 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CN101023090B (zh) * 2004-07-06 2013-03-27 雅培制药有限公司 Hiv蛋白酶抑制剂的前药
EP1809247A1 (en) 2004-09-29 2007-07-25 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
MX2007006637A (es) 2004-12-03 2007-06-19 Merck & Co Inc Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
MX2009002398A (es) 2006-09-05 2009-03-16 Schering Corp Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica.
WO2008156632A1 (en) 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US20090076097A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
ES2394952T3 (es) 2013-02-07
WO2008156632A1 (en) 2008-12-24
RS51226B (sr) 2010-12-31
CN101711237B (zh) 2013-08-07
DE602008000255D1 (de) 2009-12-17
US8258309B2 (en) 2012-09-04
US8158805B2 (en) 2012-04-17
TW200908970A (en) 2009-03-01
KR20100020033A (ko) 2010-02-19
EP2116532A1 (en) 2009-11-11
ATE536343T1 (de) 2011-12-15
ZA200909079B (en) 2011-05-25
US20120165288A1 (en) 2012-06-28
CA2692028A1 (en) 2008-12-24
CO6241121A2 (es) 2011-01-20
CA2692028C (en) 2013-06-04
EP2003120B1 (en) 2009-11-04
MX2009013565A (es) 2010-06-02
CN101711237A (zh) 2010-05-19
BRPI0813911A2 (pt) 2012-02-22
SI2003120T1 (sl) 2010-03-31
ES2356334T3 (es) 2011-04-07
CY1109766T1 (el) 2014-09-10
EP2003120A1 (en) 2008-12-17
RU2012101881A (ru) 2013-07-27
CN102424668A (zh) 2012-04-25
RU2448958C2 (ru) 2012-04-27
US20130041156A1 (en) 2013-02-14
US20110009355A1 (en) 2011-01-13
DK2003120T3 (da) 2010-03-15
PL2003120T3 (pl) 2010-04-30
AU2008267048B2 (en) 2012-05-31
EP2322509B1 (en) 2012-08-22
KR20120029480A (ko) 2012-03-26
ES2395137T3 (es) 2013-02-08
EP2116532B1 (en) 2011-12-07
EP2322509A1 (en) 2011-05-18
AU2008267048A1 (en) 2008-12-24
KR101185899B1 (ko) 2012-09-27
ATE447554T1 (de) 2009-11-15
HK1136576A1 (en) 2010-07-02
AU2008267048C1 (en) 2013-01-17
HRP20100065T1 (hr) 2010-03-31
JP2010529196A (ja) 2010-08-26
HK1127345A1 (en) 2009-09-25
EP2003120B9 (en) 2010-06-02
RU2010100821A (ru) 2011-07-20
AR066972A1 (es) 2009-09-23
BRPI0823520A2 (pt) 2013-12-17
US20090036357A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
HK1127345A1 (en) Azapeptide derivatives as hiv protease inhibitors
EP2139883A4 (en) INHIBITORS OF HIV-1 PROTEASE
IL197777A0 (en) Enantiomerically pure phosphoindoles as hiv inhibitors
SI2078001T1 (sl) Derivati diazepan-acetamida kot selektivni zaviralci 11 -hsd1
HK1127351A1 (zh) 抗病毒蛋白酶抑制劑
EP2632895A4 (en) HIV PROTEASE INHIBITORS
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
EP2304043A4 (en) HIV PROTEASE INHIBITORS AND METHOD FOR THEIR USE
IL183850A0 (en) Hiv protease inhibitors
EP2435037A4 (en) HIV PROTEASE INHIBITORS
AU2007337830A8 (en) Benzenesulfonamide derivatives as HIV protease inhibitors
EP1855672A4 (en) HIV PROTEASE INHIBITORS
EP2244571A4 (en) SMALL INHIBITORY MOLECULES OF HIV PROTEASES
ZA200804607B (en) Substituted aminophenylsulfonamide compounds as HIV protease inhibitor
EP2134336A4 (en) HIV PROTEASE INHIBITORS DERIVED FROM BENZOFURAN
EP2313426A4 (en) NOVEL PROTEASE INHIBITORS
ZA201102179B (en) Protease inhibitors
ZA200706305B (en) HIV protease inhibitors
ZA200902172B (en) Enantiomerically pure phosphoindoles as HIV inhibitors
GB0817425D0 (en) Protease inhibitors
ZA200804610B (en) Aminophenylsulfonamide derivatives as HIV protease inhibitor
GB0712176D0 (en) Protease inhibitors
GB0705213D0 (en) Protease inhibitors
GB0705212D0 (en) Protease inhibitors
GB0700369D0 (en) Protease inhibitors